Healthy stool study aims to sharpen IBD diagnosis
NCT ID NCT07089420
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measured calprotectin, a protein in stool that signals gut inflammation, in 121 healthy adults aged 22 and older. Participants collected a single stool sample at home and mailed it in. The goal is to establish what level is normal, helping doctors better tell apart inflammatory bowel disease (like Crohn's or colitis) from non-inflammatory conditions like irritable bowel syndrome.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study will give doctors a clearer normal range for calprotectin, making it easier to distinguish inflammatory bowel disease from non-inflammatory conditions.
What could go wrong
This is a small, completed study in healthy volunteers only. It does not test a treatment, so it won't directly change patient care until larger studies confirm the findings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBS (IRRITABLE BOWEL SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALPCO
Salem, New Hampshire, 03079, United States